Clinical trials: Advanced Malignant Solid Tumours
CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
A Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IBI343 in combination therapy for patients with advanced malignant solid tumors.To evaluate the efficacy and safety of IBI343 in combination…
- Conditions
- CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07483554
- Testing
- IBI343,Gemcitabine, Albumin-bound Paclitaxel
- Where
- China
- Volunteers
- 389 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced Solid Tumors
Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy
The purpose of this study is to determine if IMC-18F1 is safe for patients, and also to determine the best dose of IMC-18F1 to give to patients.
- Trial name
- NCT00782002
- Testing
- IMC-18F1
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors
A Study of ASKG315 in Patients With Advanced Solid Tumors.
The study is a Phase 1, open-label, multicenter, dose escalation study to evaluate the safety, tolerability, PK and PD of ASKG315 as a single agent in patients with advanced solid tumors.
- Trial name
- NCT05554666
- Testing
- ASKG315
- Where
- 4 sites in China
- Volunteers
- 56 people
- Sponsor
- AskGene Pharma, Inc.
Advanced Malignant Solid Tumor
A Study of MHB009C in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase I/II study of MHB009C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of…
- Trial name
- NCT07326488
- Testing
- MHB009C for Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Solid Tumor, Metastatic Tumor
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
A Phase 1 dose escalation study to determine if axatilimab as monotherapy and axatilimab in combination with a fixed dose of durvalumab will be sufficiently safe and well-tolerated at biologically active doses to warrant further…
- Conditions
- Solid Tumor, Metastatic Tumor, Locally Advanced Malignant Neoplasm, Unresectable Malignant Neoplasm
- Trial name
- NCT03238027
- Testing
- Axatilimab, Durvalumab
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Syndax Pharmaceuticals
Locally Advanced Malignant Neoplasm, Metastatic Cancer
A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors
The purpose of this study is to test the safety and efficacy of OMP-336B11. OMP-336B11 is an engineered human protein that was designed to bind to the GITR receptor on T cells and activate the immune system to recognize and…
- Trial name
- NCT03295942
- Testing
- OMP-336B11
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Neoplasms, Malignant
A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor
Primary Objectives: To determine the excretion balance and systemic exposure of radioactivity after intravenous infusion of [14C]-AVE8062 to humans To determine the pharmacokinetics of AVE8062 and RPR258063 and their contribution…
- Trial name
- NCT01063946
- Testing
- Ombrabulin (AVE8062)
- Where
- Belgium
- Volunteers
- 3 people
- Sponsor
- Sanofi
Advanced Malignant Tumors
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.
- Trial name
- NCT06764771
- Testing
- BMS-986488, Adagrasib, Cetuximab
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 437 people
- Sponsor
- Bristol-Myers Squibb
Malignant Neoplasm
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors.
- Trial name
- NCT06385925
- Testing
- TSN1611
- Where
- 19 sites in United States, China
- Volunteers
- 440 people
- Sponsor
- Tyligand Pharmaceuticals (Suzhou) Limited
Solid Tumours
A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours
This clinical trial will assess whether a medicine called artemether, currently used at a lower dose to treat malaria, could also be useful in treating cancer.
- Trial name
- LON002-002 (NCT02263950)
- Testing
- Artemether
- Where
- 2 sites in United Kingdom
- Volunteers
- 87 people
- Sponsor
- LondonPharma Ltd.
Advanced Malignant Solid Tumors
A Study of CSCJC3456 in Patients With Advanced Malignant Tumors
This is a multicenter, open-label, phase I clinical study employing a dose-escalation and cohort-expansion design to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CSCJC3456 in…
- Trial name
- NCT06717750
- Testing
- CSCJC3456 tablet
- Where
- 2 sites in China
- Volunteers
- 102 people
- Sponsor
- Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
Advanced/Metastatic Solid Tumors
Study of MHB088C for Patients With Advanced Solid Malignant Tumors
This is a Phase I/II, multicenter, open-label clinical trial with dose escalation/dose expansion/efficacy expansion phases, designed to evaluate the safety/tolerability, pharmacokinetics, immunogenicity and preliminary efficacy…
- Trial name
- NCT07102004
- Testing
- MHB088C for Injection
- Where
- China
- Volunteers
- 515 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Neoplasms Malignant
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF bispecific antibody, as a single agent in adult subjects with…
- Trial name
- NCT04047290
- Testing
- AK112
- Where
- 7 sites in Australia
- Volunteers
- 80 people
- Sponsor
- Akesobio Australia Pty Ltd
Advanced Malignant Solid Tumor
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors
VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to…
- Trial name
- NCT05477849
- Testing
- Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Virogin Biotech Co., Ltd.
Solid Tumors
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors
The primary objective is to evaluate the safety and tolerability of RC278; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC278; and determine the recommended phase 2 dose (RP2D)， and assess…
- Trial name
- NCT07105215
- Testing
- RC278
- Where
- 39 sites in China
- Volunteers
- 312 people
- Sponsor
- RemeGen Co., Ltd.
Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
The purpose of this study is to determine the safety, tolerability, and the maximum tolerated dose/recommended phase II dose of carboxyamidotriazole orotate (CTO) as a single agent in patients with advanced or metastatic solid…
- Trial name
- NCT01107522
- Testing
- CTO, CTO and Temodar®, CTO, Temodar®, Radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Tactical Therapeutics, Inc.
Advanced Malignant Solid Tumor
PRL3-Zumab in Patients With Advanced Solid Tumors
This is a multicenter, Phase II, open-label, single-dose-level (6 mg/kg) study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumors.
- Trial name
- China Phase II (NCT07541001)
- Testing
- PRL3-ZUMAB
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Intra-IMMUSG Pte Ltd
Neoplasms Malignant
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
This is an open-label, two-part study to evaluate the safety and tolerability of combination treatment with dalotuzumab + MK-2206, dalotuzumab + MK-0752, or dalotuzumab + ridaforolimus (MK-8669).
- Trial name
- NCT01243762
- Testing
- dalotuzumab, MK-0752, ridaforolimus
- Volunteers
- 47 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumor Malignancy
Study of KBA1412 in Participants With Advanced Solid Malignant Tumors
The purpose of this trial is to assess the safety and efficacy of KBA1412, a patient derived, fully human, monoclonal antibody targeting CD9, in patients with advanced solid malignant tumors
- Trial name
- NCT05501821
- Testing
- KBA1412, Pembrolizumab
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 16 people
- Sponsor
- Kling Biotherapeutics B.V.
Advanced Solid Tumors
VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors
Detailed Description: This is a multicenter, open-label, multiple-dose, first in human(FIH) Phase 1/2a trial. The Phase 1 portion uses the Bayesian optimal interval (BOIN) design to escalate doses and determine the maximum…
- Trial name
- NCT07772934
- Testing
- VBC117
- Where
- 12 sites in Australia, China
- Volunteers
- 260 people
- Sponsor
- VelaVigo Bio Inc